EG1 |
| Catalog No.GC62949 |
EG1, un inhibidor especÍfico de Pax2, se une directamente al dominio pareado de Pax2 (Kd=1,35-1,5 μM) e inhibe las interacciones Pax2-ADN. EG1 puede inhibir el desarrollo del riÑÓn embrionario, un proceso directamente dependiente de la actividad de Pax2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 693241-54-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
EG1, a specific Pax2 inhibitor, directly binds the paired domain of Pax2 (Kd=1.35-1.5 μM) and inhibits Pax2-DNA interactions. EG1 can inhibit embryonic kidney development, a process directly dependent on Pax2 activity[1].
EG1 (0-12.5 μM; 48 hours) decreases viability in Pax2 positive renal cancer cell lines[1].EG1 (0-500 μM) is capable of inhibiting Pax2 mediated expression of EGFP without significant effects on Pax2 protein levels[1].
[1]. Grimley E, et al. Inhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain. ACS Chem Biol. 2017;12(3):724-734.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *